Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

BMS’ deucravacitinib tops Otezla in two psoriasis studies

pharmatimesApril 27, 2021

Tag: BMS , deucravacitinib , Bristol Myers Squibb , Otezla , psoriasis

PharmaSources Customer Service